Daniel Nomura

Daniel Nomura

Title
Professor
Department
Dept of Chemistry
Dept of Molecular & Cell Biology
Dept of Nutritional Sciences & Toxicology
Phone
(510) 643-7258
Research Expertise and Interest
chemistry, molecular and cell biology, nutritional sciences and toxicology, metabolism, chemical biology, cancer, drug discovery, chemoproteomics, metabolomics, Alzheimer's Disease, neurodegenerative disease, undruggable, natural products chemistry
Research Description

The Nomura Research Group is focused on redefining druggability using chemoproteomic platforms to innovative transformative medicines. One of the greatest challenges that they face in discovering new disease therapies is that most proteins are considered “undruggable,” in that most proteins do not possess known binding pockets or “druggable hotspots” that small-molecules can bind to modulate protein function. Their research group addresses this challenge by advancing and applying chemoproteomic platforms to discover and pharmacologically target unique and novel druggable hotspots for disease therapy. They currently have four major research directions. Their first major focus is on developing chemoproteomics-enabled covalent ligand discovery approaches to rapidly discover small-molecule therapeutic leads that target unique and novel druggable hotspots for undruggable protein targets and incurable diseases. Their second research area focuses on covalent ligand discovery against druggable hotspots targeted by therapeutic natural products using chemoproteomic platforms to discover new therapeutic targets and synthetically tractable therapies for complex human diseases. Their third research area focuses on using chemoproteomics-enabled covalent ligand discovery platforms to expand the scope of targeted protein degradation to target and degrade undruggable proteins. Their fourth research area focuses on using chemoproteomic platforms to map on and off-targets of environmental and pharmaceutical chemicals towards discovering new toxicological mechanisms. Collectively, their lab is focused on developing next-generation transformative medicines through pioneering innovative chemical technologies to overcome challenges in drug discovery.

Major Research Directions

  1. Chemoproteomics-enabled covalent ligand discovery platforms to map and pharmacologically target druggable hotspots to tackle the undruggable proteome
  2. Covalent ligand discovery against druggable hotspots targeted by natural products for disease therapy
  3. Chemoproteomics-enabled covalent ligand discovery platforms to expand the scope of targeted protein degradation for drug discovery
  4. Using chemoproteomic platforms to map proteome-wide toxicological or therapeutic targets of environmental and pharmaceutical chemicals

 

In the News

April 13, 2012

Nomura named Searle Scholar

Daniel Nomura, an assistant professor in nutritional sciences and toxicology, is one of 15 U.S. researchers in the chemical and biological sciences to be named a 2012 Searle Scholar.

In the News

April 13, 2012

Nomura named Searle Scholar

Daniel Nomura, an assistant professor in nutritional sciences and toxicology, is one of 15 U.S. researchers in the chemical and biological sciences to be named a 2012 Searle Scholar.

Featured in the Media

Please note: The views and opinions expressed in these articles are those of the authors and do not necessarily reflect the official policy or positions of UC Berkeley.
May 4, 2020
Lisa M. Jarvis
Chemistry, molecular and cell biology, and nutritional sciences and toxicology professor Daniel Nomura, an investigator in the Berkeley-UCSF Innovative Genomics Institute, has been working with the pharmaceutical company Novartis on ways of developing drugs that harness proteins using cysteine-reactive probes. That work is now being adapted in efforts to fight COVID-19 by targeting the virus's proteins. Speaking of the main protease they're investigating, he says: "This enzyme is really well behaved and has at the center of it this amino acid -- a cysteine -- that coordinates the chemistry. ... We have this very large library of cysteine-targeting covalent ligands that we've been building out over many years. ... We thought that was a perfect way into targeting the catalytic cysteine of what I would consider a highly druggable protein."
Loading Class list ...
.